Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

StatusActive, Not Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 302 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv302
  2. Study sites revised (140)v301
  3. Study sites revised (140)v300
  4. Study sites revised (140)v299
  5. Study sites revised (140)v298
Show 45 earlier versionsHide 45 earlier versions
  1. Study completion date: Feb 22, 2026 to Mar 6, 2027v297
  2. Study sites revised (140)v296
  3. Re-verified, no change to tracked fieldsv295
  4. Study sites revised (140)v294
  5. Study sites revised (140)v293
  6. Study sites revised (140)v292
  7. Study completion date: Feb 22, 2025 to Feb 22, 2026v291
  8. Re-verified, no change to tracked fieldsv290
  9. Study sites revised (140)v289
  10. Study sites revised (140)v288
  11. Study sites revised (140)v287
  12. Study sites revised (140)v286
  13. Study sites revised (140)v285
  14. 2 versions Re-verified since Jul 2, 2024, no change to tracked fieldsv283-v284
  15. Study sites revised (140)v282
  16. Study sites revised (140)v281
  17. Study completion date: Feb 22, 2025v280
  18. 8 versions Re-verified since Jun 28, 2022, no change to tracked fieldsv272-v279
  19. Study sites revised (140)v271
  20. Study sites revised (140)v270
  21. 2 versions Re-verified since Oct 12, 2021, no change to tracked fieldsv268-v269
  22. Study sites revised (140)v267
  23. 3 versions Re-verified since Apr 9, 2021, no change to tracked fieldsv264-v266
  24. Study sites revised (140)v263
  25. Study sites revised (140)v262
  26. 2 versions Re-verified since Sep 15, 2020, no change to tracked fieldsv260-v261
  27. Study sites revised (140)v259
  28. Study sites revised (140)v258
  29. Re-verified, no change to tracked fieldsv257
  30. Study sites revised (140)v256
  31. 3 versions Re-verified since Jan 20, 2020, no change to tracked fieldsv253-v255
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase III trial studies lenalidomide to see how well it works compared to a placebo in treating patients with multiple myeloma who are undergoing autologous stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Giving lenalidomide after autologous stem cell transplant may be an effective treatment for multiple myeloma.
Trial Details
NCT Number NCT00114101
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Related terms Multiple Myeloma, Smoldering Multiple Myeloma
Enrollment 460 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov